AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22126550 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxotere plus poldine intravenous chemotherapy (A1)
Number of subjects: 27
Study 22126550 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxotere intravenous chemotherapy combined with poldine intraperitoneal chemotherapy (A2)
Number of subjects: 27
Study 22126550 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus poldine intravenous chemotherapy (B1)
Number of subjects: 27
Study 22126550 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel intravenous chemotherapy combined with poldine intraperitoneal chemotherapy (B2)
Number of subjects: 27
Study 19508157 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent IL-2 therapy
Number of subjects: 130
Study 19508157 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 130
Study 16564803 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral lateral rectus (BLR) recessions
Number of subjects: 124
Study 16564803 — intervention group
Group type: COMPARATOR
Intervention: Unilateral recess-resect (RR) procedure on the nondominant eye
Number of subjects: 124
Study 12968319 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0
Study 12968319 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 10700435 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrocentesis (synovial fluid aspiration) before injecting 20 mg triamcinolone hexacetonide
Number of subjects: 147
Study 10700435 — intervention group
Group type: COMPARATOR
Intervention: No arthrocentesis before injecting 20 mg triamcinolone hexacetonide
Number of subjects: 147
Study 9305485 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg/day
Number of subjects: 16
Study 9305485 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg/day
Number of subjects: 16
Study 8419599 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic surfactant at birth
Number of subjects: 150
Study 8419599 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue surfactant after clinical diagnosis of respiratory distress syndrome
Number of subjects: 150
Study 8419599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 2995755 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy under hyperbaric oxygenation (HBO)
Number of subjects: 120
Study 29975804 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 60
Study 29975804 — intervention group
Group type: COMPARATOR
Intervention: Chemical neurolysis (alcohol)
Number of subjects: 60
Study 27130272 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped collaborative care intervention targeting PTSD and comorbidity
Number of subjects: 960
Study 27130272 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (Control)
Number of subjects: 960
Study 23334623 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint aspiration
Number of subjects: 167
Study 23334623 — intervention group
Group type: COMPARATOR
Intervention: No aspiration (Control)
Number of subjects: 167
Study 22019031 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of low dose chemoprophylaxis
Number of subjects: 176
Study 15640321 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg daily for 4 weeks
Number of subjects: 14
Study 15640321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 15640321 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 14
Study 12370885 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-free environmental control system (ECS)
Number of subjects: 10
Study 9639076 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg methylphenidate
Number of subjects: 32
Study 9639076 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg methylphenidate
Number of subjects: 32
Study 9639076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 7807300 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine surfactant therapy
Number of subjects: 119
Study 7807300 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 119
Study 2775613 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine
Number of subjects: 5
Study 2775613 — intervention group
Group type: COMPARATOR
Intervention: Dextromethorphan
Number of subjects: 5
Study 2775613 — intervention group
Group type: COMPARATOR
Intervention: Low affinity component
Number of subjects: 5
Study 57131 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous grass extract
Number of subjects: 0
Study 57131 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-soluble timothy (WST) in alginate
Number of subjects: 0
Study 57131 — intervention group
Group type: COMPARATOR
Intervention: Injections of antigen D in alginate
Number of subjects: 0
Study 29627897 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefiderocol 2 g every 8 h with 3-h infusion (3, 6, and 9 doses with furosemide, metformin, and rosuvastatin respectively)
Number of subjects: 39
Study 29627897 — intervention group
Group type: COMPARATOR
Intervention: Furosemide 20 mg
Number of subjects: 39
Study 29627897 — intervention group
Group type: COMPARATOR
Intervention: Metformin 1000 mg
Number of subjects: 39
Study 29627897 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg
Number of subjects: 39
Study 26761585 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy
Number of subjects: 75
Study 26761585 — intervention group
Group type: COMPARATOR
Intervention: Total abdominal hysterectomy
Number of subjects: 75
Study 26761585 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 75
Study 24659610 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplements (10 supplements daily including 100 mg resveratrol, 800 mg each of green, black, and white tea extract, 250 mg pomegranate extract, 650 mg quercetin, 500 mg acetyl-l-carnitine, 600 mg lipoic acid, 900 mg curcumin, 1 g sesamin, 1.7 g cinnamon bark extract, and 1.0 g fish oil)
Number of subjects: 56
Study 24659610 — intervention group
Group type: COMPARATOR
Intervention: Control group (daily multivitamin/mineral supplement)
Number of subjects: 56
Study 22551128 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose radioiodine (1.1 GBq [30 mCi])
Number of subjects: 421
Study 22551128 — intervention group
Group type: COMPARATOR
Intervention: High-dose radioiodine (3.7 GBq [100 mCi])
Number of subjects: 421
Study 22551128 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin alfa
Number of subjects: 421
Study 22551128 — intervention group
Group type: COMPARATOR
Intervention: Thyroid hormone withdrawal
Number of subjects: 421
Study 22551128 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose radioiodine plus thyrotropin alfa
Number of subjects: 421
Study 22551128 — intervention group
Group type: COMPARATOR
Intervention: High-dose radioiodine plus thyroid hormone withdrawal
Number of subjects: 421
Study 22551128 — intervention group
Group type: COMPARATOR
Intervention: High-dose radioiodine plus thyrotropin alfa
Number of subjects: 421
Study 22551128 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose radioiodine
Number of subjects: 421
Study 22551128 — intervention group
Group type: COMPARATOR
Intervention: High-dose radioiodine
Number of subjects: 421
Study 20418185 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondistressed married participants
Number of subjects: 255
Study 20418185 — intervention group
Group type: COMPARATOR
Intervention: Distressed married participants
Number of subjects: 255
Study 20418185 — intervention group
Group type: COMPARATOR
Intervention: Unmarried participants
Number of subjects: 255
Study 18386209 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions for suicidal youths; specific interventions not detailed in the abstract.
Number of subjects: 0
Study 18386209 — intervention group
Group type: COMPARATOR
Intervention: Standard of care treatments; specific treatments not detailed in the abstract.
Number of subjects: 0
Study 15970422 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program for developing communication skills of health professionals (physicians, physiotherapists, and nurses) and reorganization of patient information schemes.
Number of subjects: 199
Study 15970422 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered breathing exercises (intermediary outcome parameter).
Number of subjects: 199
Study 15970422 — intervention group
Group type: COMPARATOR
Intervention: Not available.
Number of subjects: 199
Study 12947065 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 12‐9566 800 mg orally bid continuously
Number of subjects: 277
Study 12947065 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine 1,000 mg/m2 intravenously on specified days
Number of subjects: 277
Study 12947065 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality-of-life analysis
Number of subjects: 277
Study 10817010 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hormone replacement therapy alone (Group A)
Number of subjects: 100
Study 10817010 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of a half dose hormone replacement therapy and anxiolytic drug (Group B)
Number of subjects: 100
Study 8865765 — intervention group
Group type: EXPERIMENTAL
Intervention: A/A gain settings of 0.75 and 1.0
Number of subjects: 0
Study 8865765 — intervention group
Group type: EXPERIMENTAL
Intervention: D/A gain settings of 0.5 cm/degree and 0.67 cm/degree
Number of subjects: 0
Study 8865765 — intervention group
Group type: EXPERIMENTAL
Intervention: D/A gain settings
Number of subjects: 0
Study 1508382 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium folinate (Citofolin Bracco S.p.A.) 15 mg/day per os starting from the 12th or 20th week of gestation
Number of subjects: 0
Study 1508382 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 0
Study 6396639 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 151
Study 6396639 — intervention group
Group type: EXPERIMENTAL
Intervention: Long follow-up and nicotine gum
Number of subjects: 151
Study 6396639 — intervention group
Group type: EXPERIMENTAL
Intervention: Short follow-up and nicotine gum
Number of subjects: 151
Study 6396639 — intervention group
Group type: EXPERIMENTAL
Intervention: Long follow-up and no gum
Number of subjects: 151
Study 6396639 — intervention group
Group type: COMPARATOR
Intervention: Short follow-up and no gum
Number of subjects: 151
Study 6396639 — intervention group
Group type: EXPERIMENTAL
Intervention: Long follow-up
Number of subjects: 151
Study 31208092 — intervention group
Group type: EXPERIMENTAL
Intervention: Snack condition (10% of 24 h energy intake)
Number of subjects: 44
Study 31208092 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal condition (30% of 24 h energy intake)
Number of subjects: 44
Study 31208092 — intervention group
Group type: COMPARATOR
Intervention: No Eating condition (no food during the night)
Number of subjects: 44
Study 29446069 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-541468 (5-200 mg single oral dose)
Number of subjects: 0
Study 29446069 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-541468 (≥25 mg)
Number of subjects: 0
Study 27777279 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75/150 mg every 2 weeks
Number of subjects: 4974
Study 27777279 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Number of subjects: 4974
Study 27777279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4974
Study 24412583 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (45 min)
Number of subjects: 50
Study 24412583 — intervention group
Group type: COMPARATOR
Intervention: Control condition (45 min)
Number of subjects: 50
Study 22897508 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 165
Study 22897508 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with alfentanil
Number of subjects: 165
Study 20621444 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized visual perception and visual-motor integration training (8 sessions) with a home training program
Number of subjects: 26
Study 20621444 — intervention group
Group type: COMPARATOR
Intervention: Conventional handwriting training by teachers (remedial handwriting exercises)
Number of subjects: 26
Study 17917556 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (mean dose 165 mg/day, SD=73.8; range 75-300 mg)
Number of subjects: 30
Study 17917556 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (mean dose 26 mg/day, SD=15.04; range 10-60 mg)
Number of subjects: 30
Study 16047553 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal preparations
Number of subjects: 3160
Study 12381630 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure patients
Number of subjects: 80
Study 12381630 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 80
Study 10367513 — intervention group
Group type: EXPERIMENTAL
Intervention: B.A.R. (Biofragmentable Anastomosis Ring)
Number of subjects: 45
Study 10367513 — intervention group
Group type: EXPERIMENTAL
Intervention: GLA stapling device
Number of subjects: 45
Study 10367513 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual suture with interrupted stitches double layer (vicryl)
Number of subjects: 45
Study 7480525 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment (four different compounds)
Number of subjects: 49
Study 7480525 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during the run-in period)
Number of subjects: 49
Study 2265308 — intervention group
Group type: EXPERIMENTAL
Intervention: herbal yeast food supplement
Number of subjects: 16
Study 2265308 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 299462 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin (20 mg) and hypertonic saline (NaCl 5 and 10 g) with oxytocin
Number of subjects: 385
Study 31724971 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental involvement in manual reduction (physician's and parent's finger on the patient's radial head)
Number of subjects: 150
Study 31724971 — intervention group
Group type: COMPARATOR
Intervention: Physician's finger only on the patient's radial head (control group)
Number of subjects: 150
Study 31801605 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed messages (GF)
Number of subjects: 96
Study 31801605 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed messages (LF)
Number of subjects: 96
Study 31801605 — intervention group
Group type: COMPARATOR
Intervention: Routine education (Control)
Number of subjects: 96
Study 27299887 — intervention group
Group type: EXPERIMENTAL
Intervention: DCS therapy (docetaxel at 40 mg/m2, cisplatin at 60 mg/m2 on day 1, S-1 at 40 mg/m2 twice daily for 2 weeks) followed by gastrectomy with D2 plus para-aortic nodal dissection
Number of subjects: 52
Study 25958716 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral chelated zinc with standard treatment (oral prednisolone)
Number of subjects: 30
Study 25958716 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (oral prednisolone) alone
Number of subjects: 30
Study 23637065 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa with skimmed milk intervention (40 g/day of cocoa powder with 500 mL skimmed milk)
Number of subjects: 20
Study 23637065 — intervention group
Group type: COMPARATOR
Intervention: Skimmed milk intervention (500 mL/day of skimmed milk)
Number of subjects: 20
Study 21068698 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombomodulin alfa (TM‐α) 0.06 mg·kg for 30 min once daily for 6 days
Number of subjects: 80
Study 21068698 — intervention group
Group type: COMPARATOR
Intervention: Heparin 8 U·kg·h for 24 h for 6 days
Number of subjects: 80
Study 19840634 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement of fiber post (DT Light Post) in subgroups post
Number of subjects: 90
Study 19840634 — intervention group
Group type: COMPARATOR
Intervention: No post (no root canal retention) in subgroups no post
Number of subjects: 90
Study 19840634 — intervention group
Group type: COMPARATOR
Intervention: No post in no-wall group
Number of subjects: 90
Study 19840634 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement of fiber post in no-wall group
Number of subjects: 90
Study 17061634 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose hydrocortisone supplementation (Group C)
Number of subjects: 113
Study 17061634 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation (Group B)
Number of subjects: 113
Study 17061634 — intervention group
Group type: EXPERIMENTAL
Intervention: Septic shock patients (Group A)
Number of subjects: 113
Study 17061634 — intervention group
Group type: COMPARATOR
Intervention: Relative adrenal insufficiency presence in all groups
Number of subjects: 113
Study 15557490 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (IFNB-1b) at a dosage of 8 MIU (250 mcg)
Number of subjects: 0
Study 15557490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11741551 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary enalaprilat (50 microg)
Number of subjects: 22
Study 11741551 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 22
Study 9706832 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week lisinopril treatment
Number of subjects: 6405
Study 9706832 — intervention group
Group type: EXPERIMENTAL
Intervention: Predischarge echocardiography
Number of subjects: 6405
Study 8154278 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a key and compression of the lag screw
Number of subjects: 153
Study 8154278 — intervention group
Group type: COMPARATOR
Intervention: No key and compression of the lag screw
Number of subjects: 153
Study 3358882 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nifedipine
Number of subjects: 12
Study 3358882 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 12
Study 3358882 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 12
Study 30801373 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 286
Study 30801373 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 286
Study 30801373 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment (observational cohort)
Number of subjects: 286
Study 30801373 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment (observational cohort)
Number of subjects: 286
Study 30801373 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment (overall responder analysis)
Number of subjects: 286
Study 30170285 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) infusion (0.5 μg/kg per min for 4 hours)
Number of subjects: 42
Study 30170285 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 42
Study 26313650 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (600 mg)
Number of subjects: 8
Study 26313650 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (1200 mg)
Number of subjects: 8
Study 26313650 — intervention group
Group type: EXPERIMENTAL
Intervention: Δ9‐THC (5 mg)
Number of subjects: 8
Study 26313650 — intervention group
Group type: EXPERIMENTAL
Intervention: Δ9‐THC (15 mg)
Number of subjects: 8
Study 26313650 — intervention group
Group type: EXPERIMENTAL
Intervention: Δ9‐THC (30 mg)
Number of subjects: 8
Study 26313650 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin and Δ9‐THC (combined)
Number of subjects: 8
Study 26313650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 24832373 — intervention group
Group type: EXPERIMENTAL
Intervention: Oocyte retrieval by trainees
Number of subjects: 3
Study 24832373 — intervention group
Group type: COMPARATOR
Intervention: Senior operator's oocyte retrieval
Number of subjects: 3
Study 22785500 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.10 mg nor-β-CFT
Number of subjects: 25
Study 22785500 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.20 mg nor-β-CFT
Number of subjects: 25
Study 22785500 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg nor-β-CFT
Number of subjects: 25
Study 22785500 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.30 mg nor-β-CFT
Number of subjects: 25
Study 22785500 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.10 mg nor-β-CFT)
Number of subjects: 25
Study 20124183 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab 420 mg (arm A)
Number of subjects: 79
Study 20124183 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab 1,050 mg (arm B)
Number of subjects: 79
Study 20124183 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both arms)
Number of subjects: 79
Study 20124183 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab (both arms)
Number of subjects: 79
Study 16860874 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping with Depression (CWD) course
Number of subjects: 104
Study 16860874 — intervention group
Group type: COMPARATOR
Intervention: Assessment-and-advice-only control group
Number of subjects: 104
Study 15813473 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor exercises during pregnancy and puerperium
Number of subjects: 72
Study 15813473 — intervention group
Group type: COMPARATOR
Intervention: No pelvic floor exercises
Number of subjects: 72
Study 10703779 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 401
Study 10703779 — intervention group
Group type: COMPARATOR
Intervention: Formula feeding
Number of subjects: 401
Study 9493654 — intervention group
Group type: EXPERIMENTAL
Intervention: CFA patients
Number of subjects: 20
Study 9493654 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 8450517 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (4.55 g/day of EPA and DHA)
Number of subjects: 18
Study 8450517 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg twice daily) added to fish oil
Number of subjects: 18
Study 8450517 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (20 mg twice daily) added to placebo
Number of subjects: 18
Study 2429687 — intervention group
Group type: EXPERIMENTAL
Intervention: Citanest with Octapressin (prilocaine 3% with 0.03 i.u./ml. of felypressin)
Number of subjects: 50
Study 2429687 — intervention group
Group type: COMPARATOR
Intervention: No anaesthesia
Number of subjects: 50